Authors:Hannan M. Braun; Jessica L. Taylor Sarah Axelrath Abstract: Sublingual buprenorphine, approved for treatment of opioid use disorder since 2002, is most commonly available in co-formulation with naloxone. Naloxone is an opioid antagonist minimally absorbed when sublingu... PubDate: 2024-07-30T00:00:00Z
Authors:Jed E. Rose; Frederique M. Behm, Gal Cohen, Perry N. Willette, Tanaia L. Botts David R. Botts Abstract: Electronic nicotine delivery systems (ENDS) offer a promising approach to tobacco harm reduction, but many people use both ENDS and combustible cigarettes (“dual use”), which undermines potential risk reductio... PubDate: 2024-07-29T00:00:00Z
Authors:Boogyung Seo; William Rioux, Adrian Teare, Nathan Rider, Stephanie Jones, Pamela Taplay S. Monty Ghosh Abstract: Supervised consumption sites (SCS) and overdose prevention sites (OPS) have been implemented across Canada to mitigate harms associated with illicit substance use. Despite their successes, they still contend w... PubDate: 2024-07-27T00:00:00Z
Authors:Erin Bredenberg; Catherine Callister, Ashley Dafoe, Brooke Dorsey Holliman, Sarah E. Rowan Susan L. Calcaterra Abstract: The hepatitis C virus (HCV) causes chronic and curable disease with a substantial burden of morbidity and mortality across the globe. In the United States (US) and other developed countries, incidence of HCV i... PubDate: 2024-07-25T00:00:00Z
Open Access journal
